IRulya Therapeutics Inc. SEC filings IRLA
IRulya Therapeutics Inc. has 462 filings in SEC EDGAR's recent list, going back to Jan 5, 2016. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Oct 8, 2026 | — |
| S-3/A | Filing | Aug 5, 2026 | — |
| S-3 | Shelf registration | Jul 31, 2026 | — |
| S-8 | Employee stock plan registration | Apr 17, 2026 | — |
| 424B5 | Prospectus supplement | Oct 17, 2025 | — |
| 424B5 | Prospectus supplement | Aug 5, 2025 | — |
| S-3 | Shelf registration | Jul 25, 2025 | — |
| S-8 | Employee stock plan registration | Mar 24, 2025 | — |
| 424B5 | Prospectus supplement | Mar 24, 2025 | — |
| 424B5 | Prospectus supplement | Dec 27, 2024 | — |
| S-3 | Shelf registration | Dec 18, 2024 | — |
| S-8 | Employee stock plan registration | Apr 1, 2024 | — |
| S-8 | Employee stock plan registration | Mar 15, 2023 | — |
| S-8 | Employee stock plan registration | May 20, 2022 | — |
| 424B5 | Prospectus supplement | May 19, 2022 | — |
| POS AM | Filing | Mar 4, 2022 | — |
| S-8 | Employee stock plan registration | Mar 1, 2022 | — |
| 424B5 | Prospectus supplement | Dec 23, 2021 | — |
| S-8 | Employee stock plan registration | Mar 1, 2021 | — |
| S-3ASR | Automatic shelf registration | Jun 1, 2020 | — |
| 424B3 | Prospectus | Apr 13, 2020 | — |
| S-1 | Registration statement | Apr 7, 2020 | — |
| S-8 | Employee stock plan registration | Mar 16, 2020 | — |
| 424B4 | Prospectus | May 9, 2019 | — |
| S-8 | Employee stock plan registration | May 9, 2019 | — |
| S-1/A | Amended registration statement | Apr 29, 2019 | — |
| S-1/A | Amended registration statement | Apr 16, 2019 | — |
| S-1 | Registration statement | Apr 12, 2019 | — |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IRLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1662774
- Former names
- Quince Therapeutics, Inc. (until Oct 9, 2026); Cortexyme, Inc. (until Aug 1, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.